Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 GeneticVariation disease BEFREE Secondary end points included any myocardial ischemia, respiratory and early procedural complications, acute kidney injury (AKI) according to RIFLE criteria (Risk, Injury, Failure, Loss of kidney function, and End-stage renal failure), spinal cord ischemia, a composite of these complications, and postoperative intensive care unit length of stay. 29576405 2018
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 Biomarker disease BEFREE The novel RIFLE (pediatric RIFLE for pediatrics), Acute Kidney Injury Network (AKIN) and Kidney Disease Improving Global Outcomes (KDIGO) criteria have brought about unified diagnostic standards and comparable results for AKI after cardiac surgery. 29891225 2019
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 Biomarker disease BEFREE Critically ill patients at risk of AKI and admitted to a general intensive care unit were categorised after initial resuscitation according to the RIFLE criteria for AKI. 22005822 2012
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 Biomarker disease BEFREE The main outcomes were severe infusion-related adverse events according to the Common Terminology Criteria for Adverse Events and the renal failure category of RIFLE criteria for acute kidney injury (AKI) during treatment. 29038262 2018
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 Biomarker disease BEFREE Acute renal failure (ARF) was defined as an increment of serum creatinine 3 times greater than baseline and/or at least 75% reduction in baseline eGFR as per RIFLE Classification. 30387529 2019
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 Biomarker disease BEFREE The RIFLE criteria were used to define the presence of acute kidney injury. 31196131 2019
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 GeneticVariation disease BEFREE Studies of adult major trauma patients admitted to critical care that applied consensus AKI criteria (risk injury failure loss end stage [RIFLE], AKI network, or kidney disease improving global outcomes) and reported clinical outcomes were assessed (PROSPERO Registration: CRD42017056781). 30358765 2019
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 GeneticVariation disease BEFREE Three hundred thirty nine patients were included; AKI developed in 141 (41.6%) patients; RISK in 27 (8%) patients; INJURY in 25 (7%); FAILURE in 89 (26%) by the RIFLE criteria. 28143505 2017
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 Biomarker disease BEFREE The impact of AKI and renal failure (using RIFLE score) in 1-year mortality was analysed, along with other confounding variables. 29501603 2018
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 Biomarker disease BEFREE According to RIFLE criteria; AKI-Risk, AKI-Injury and AKI-Failure occurred in 26 (2.6%), 9 (0.9%) and 11 (1.1%) patients, respectively. 29757568 2018
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 Biomarker disease BEFREE Nonsignificantly more COMT LL patients developed RIFLE-AKI compared with non-LL patients (p = 0.11). 25525983 2014
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 Biomarker disease BEFREE A literature search was performed using MEDLINE, EMBASE and Cochrane Database from inception until July 2018 to identify studies assessing the incidence of AKI (using standard AKI definitions of RIFLE, AKIN, and KDIGO classifications) in patients undergoing THA. 30634487 2019
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 Biomarker disease BEFREE Urine output criteria detected AKI in patients without AKI at ICU admission in a median of 13 h (IQR 7-22 h; using RIFLE definition) after admission compared to a median of 24 h using serum creatinine criteria (IQR24-48 h). 28219327 2017
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 Biomarker disease BEFREE There was no difference in survival between patients experiencing AKI according to the RIFLE or AKIN criteria without RRT requirement and patients without AKI. 31851363 2020
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 GeneticVariation disease BEFREE End points included post-operative death; acute kidney injury (AKI) defined by the RIFLE (Risk, Injury, Failure, Loss of function, End stage renal disease) criteria; and long term follow-up with freedom from chronic renal decline (CRD) and any graft related complications. 31530501 2020
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 GeneticVariation disease BEFREE This study evaluated the incidence, predictors and prognosis of AKI associated with scrub typhus according to the RIFLE (risk, injury, failure, loss, end-stage kidney disease) criteria. 28298367 2017
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 Biomarker disease BEFREE Using RIFLE criteria, 6 patients in the control group and 2 patients in the nicardipine group were classified as having acute kidney injury. 27231835 2017
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 GeneticVariation disease BEFREE After suprarenal clamping, 2 retrospective studies used the RIFLE criteria to define the incidence of AKI, and the pooled AKI rate was 36.8%. 27890835 2017
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 GeneticVariation disease BEFREE AKI was defined and graded using either the modified RIFLE criteria or the Pediatrics RIFLE criteria, while CKD was graded using the KDIGO criteria. 29212494 2017
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 GeneticVariation disease BEFREE Of 380 children, 53 children (14%) had AKI (met any of the RIFLE criteria). 26752169 2017
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 GeneticVariation disease BEFREE None of the patients developed acute kidney injury according to RIFLE criteria. 31756180 2019
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 GeneticVariation disease BEFREE Multivariate logistic regression was used to determine the best predictive models for AKI (RIFLE [renal Risk, Injury, Failure, Loss of renal function and End-stage renal disease] classification), incremental predictive value of minimum cardiopulmonary bypass DO<sub>2</sub>i, and optimal threshold. 31238029 2019
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 GeneticVariation disease BEFREE AKI was defined according to the RIFLE criteria (risk, injury, failure, loss of kidney function, and end-stage kidney disease): increase by 50% in sCr or reduction of at least 25% of estimated glomerular filtration rate (eGFR) from baseline. 29472806 2018
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 GeneticVariation disease BEFREE Group I also manifested significantly higher incidence of AKI than group II (62.7% vs. 28.5%, p = 0.005), even when stratified according to RIFLE criteria ('Risk' 33.9% vs. 10.7%; 'Injury' 10.2% vs. 8.9%; 'Failure' 18.6% vs. 8.9%; p = 0.03). 28353411 2017
Entrez Id: 90678
Gene Symbol: LRSAM1
LRSAM1
0.100 Biomarker disease BEFREE Prevalence of AKI based on RIFLE criteria was 60% and 15% in high dose and conventional dose groups, respectively (P = 0.003). 28979332 2017